Files include the data presented in the manuscript entitled " Layered PCL scaffolds modified with bioactive additives fabricated by electrospinning and 3D-printing for the nasal bone and cartilage defects " by A.Kurowska et al.(Materials & Design, 2023, 233, 112255 https://doi.org/10.1016/j.matdes.2023.112255).
In this work, a method for fabricating layered materials supporting the reconstruction of nasal tissues by combining the 3D/fused deposition modeling (FDM) technology with electrospinning (ES) is presented. Polycaprolactone (PCL) scaffolds modified with bioglass (BG) and zinc (Zn)-doped BG were printed from the connectable filaments sticks. Then, using the ES, a nanofibrous membrane with particles of the pharmaceutical drug Osteogenon (OST), was applied directly on a spatial scaffold. The layered scaffolds were investigated by Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and micro-computed tomography (µCT). The bioactivity and biocompatibility of the scaffolds were evaluated by in vitro studies. The results indicated that the presence of the OST drug in the top layer of scaffolds promoted bioactivity. The presence of a membrane had a positive effect on the production and secretion of aggrecan (Agg), and incorporation of BG particles significantly improved the production and secretion of collagen type II (Col2). Each of the introduced PCL modifications leads to articular cartilage cell (NHAC-kn) viability improvement and results in a decrease in the cytotoxicity of the material. Moreover, in the long-term culture, cell proliferation was positively affected by the introduction of the OST-modified membrane and also by the addition of Zn-doped BG particles.
Data (.txt. and xlsx) includes:
Fig. 3a. Analysis made from the side of the upper layer of the scaffolds:
· ATR_FTIR spectra of the OSTEOGENON drug
· ATR_FTIR spectra of the PCL scaffold (pure polycaprolactone scaffold)
· ATR_FTIR spectra of the PCL/PCL_OST layered scaffolds (pure PCL scaffold/PCL electrospun membrane modified with OSTEOGENON drug)
· ATR_FTIR spectra of the PCL_BG/PCL_OST layered scaffolds (Polycaprolactone scaffold modified with Bioglass/ Polycaprolactone electrospun membrane modified with OSTEOGENON drug)
· ATR_FTIR spectra of the PCL_BG_Zn/PCL_OST layered scaffolds (Polycaprolactone scaffold modified with Zinc doped Bioglass/ Polycaprolactone electrospun membrane modified with OSTEOGENON drug)
Fig. 3b. Analysis made from the side of the bottom layer of the scaffolds:
· ATR_FTIR spectra of the BG_powder (Bioglass powder)
· ATR_FTIR spectra of the BG_Zn_powder (Zinc doped bioglass powder)
· ATR_FTIR spectra of the PCL_PCL_OST layered scaffolds (pure PCL scaffold/PCL electrospun membrane modified with OSTEOGENON drug)
· ATR_FTIR spectra of the PCL_BG/PCL_OST layered scaffolds (Polycaprolactone scaffold modified with Bioglass/Polycaprolactone electrospun membrane modified with OSTEOGENON drug)
· ATR_FTIR of the PCL_BG_Zn/PCL_OST layered scaffolds (Polycaprolactone scaffold modified with Zinc doped Bioglass/ Polycaprolactone electrospun membrane modified with OSTEOGENON drug)
Fig 5. EDS analysis of the layered scaffolds after 7 days of incubation in SBF (Simulated Body Fluid):
· Fig 5a. PCL/PCL_OST_ layered scaffolds after 7 days in SBF (pure PCL scaffold/PCL electrospun membrane modified with OSTEOGENON drug)
· Fig 5c. PCL_BG/PCL_OST_layered scaffolds after 7 days in SBF (Polycaprolactone scaffold modified with Bioglass/ Polycaprolactone electrospun membrane modified with OSTEOGENON drug)
· Fig. 5e. PCL_BG_Zn/PCL_OST_ layered scaffolds after 7 days in SBF (Polycaprolactone scaffold modified with Zinc doped Bioglass/ Polycaprolactone electrospun membrane modified with OSTEOGENON drug)
Fig 9e. Histogram of the distribution of BG_Zn_particles in a lower layer of the leyered PCL_BG_Zn/PCL_OST scaffolds before Simulated Body Fluid (SBF) incubation
Fig 10e. Histogram of the distribution of BG_Zn_particles in a lower layer of the layered PCL_BG_Zn/PCL_OST scaffolds after 14 days in Simulated Body Fluid (SBF).
Fig. 11a The results of viability of NHAC-kn after 7 and 14 days of culture in direct contact with the PCL-based scaffolds
Fig. 11b The rasults of proliferation of NHAC-kn after 7 and 14 days of culture in direct contact with the PCL-based scaffolds
Fig. 11c The results of cytotoxicity of the scaffolds towards NHAC-kn cells after 7 and 14 days of culture.
(2024)
